Dabigatran May Pose Excess Risk in Patients With Mechanical Valves
Patients with mechanical heart valves may be the last group considered for transition from warfarin to a novel anticoagulant; for now, at least, not to dabigatran. (Source: Consultant Live)
Source: Consultant Live - September 9, 2013 Category: Primary Care Source Type: news

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involvi...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

Hokusai-VTE study suggests certain sub-groups of venous thromboembolism patients may need review
In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 3, 2013 Category: Consumer Health News Tags: Vascular Source Type: news

Edoxaban (Lixiana) Noninferior to WarfarinEdoxaban (Lixiana) Noninferior to Warfarin
The factor Xa inhibitor joins others in this new class of oral anticoagulants in rivaling the older agent for efficacy in acute VTE and outclassing it for safety in a major randomized trial. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

New Daiichi drug vies for slice of clot prevention market
A new clot preventer from Daiichi Sankyo proved effective as warfarin in treating venous thromboembolism and caused less bleeding. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 1, 2013 Category: Pharmaceuticals Source Type: news

New Daiichi drug vies for slice of clot prevention market
AMSTERDAM (Reuters) - A new clot preventer from Daiichi Sankyo proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused less bleeding, a large clinical trial found. (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Hokusai-VTE Study: Once-daily edoxaban matches warfarin for averting recurrent DVT, PE
The factor Xa inhibitor joins others in this new class of oral anticoagulants in rivaling the older agent for efficacy in acute VTE and outclassing it for safety in a major randomized trial. (Source: theHeart.org)
Source: theHeart.org - September 1, 2013 Category: Cardiology Source Type: news

ESC: Edoxaban Bests Warfarin on Safety in VTE (CME/CE)
AMSTERDAM (MedPage Today) -- Edoxaban, a novel factor Xa inhibitor, met its primary endpoint in a noninferiority study that pitted it against warfarin for treatment of symptomatic venous thromboembolism. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 1, 2013 Category: Cardiology Source Type: news

Disappointing Results with Boehringer's Pradaxa for Mechanical Valves
Despite being more durable than bioprosthetic valves, mechanical heart valves are often not chosen because of the requirement for lifelong anticoagulant therapy. It has been hoped that the newer generation of oral anticoagulants might eventually replace warfarin, making anticoagulation more tolerable and better accepted, since these agents don't require continuous monitoring and have much fewer serious interactions with other drugs and food. So far, however, there has been no convincing demonstration that the the newer agents are as safe and effective as warfarin for this indication. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Hokusai-VTE study suggests certain sub-groups of venous thromboembolism patients may need review
(European Society of Cardiology) In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin, according to the results of the Hokusai-VTE trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2013 Category: Global & Universal Source Type: news

Outcomes of Apixaban vs Warfarin by Type of AFOutcomes of Apixaban vs Warfarin by Type of AF
Are the risks of stroke lower with apixaban than warfarin -- regardless of AF type and duration? European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

How to stop bleeding in the ER caused by warfarin
(American College of Emergency Physicians) Prothrombin complex concentrates (PCCs) are faster and more effective than fresh frozen plasma at reversing hemorrhage caused by the anti-coagulant warfarin, despite plasma being the most commonly used therapy. A literature review published last month in Annals of Emergency Medicine suggests that physicians in the United States should join those around the world in following recommendations of multiple specialty organizations to use PCCs as the first line of defense in this common and life-threatening emergency. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 2, 2013 Category: Global & Universal Source Type: news

Pharmacy Voice data highlights community pharmacy’s safety role in high-risk medicines pathway
Audit data collected from 2,773 pharmacies in England and Wales found that just under 14% of people taking methotrexate (to treat arthritis), lithium (to treat bipolar disorder) or warfarin (to thin the blood) are not having their regular blood tests which are used to check they are receiving the correct dose.  In the course of the audit, community pharmacists identified 425 patients who were showing signs of toxicity. (Source: NHS Networks)
Source: NHS Networks - August 1, 2013 Category: UK Health Authors: Maria Axford Source Type: news

Young HF Patients OK with Warfarin (CME/CE)
(MedPage Today) -- The benefit of warfarin over aspirin in heart failure patients appears to be age-related, with younger patients accounting for the greater share of risk reduction, a subanalysis of the WARCEF trial found. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 30, 2013 Category: Consumer Health News Source Type: news

Medication Errors in Adults—Case #1: Warfarin
This agent has a large number of drug-drug and drug-food interactions, and there is a need for increased INR monitoring. (Source: Consultant Live)
Source: Consultant Live - July 29, 2013 Category: Primary Care Source Type: news

Could new anticoagulants replace Coumadin?
Anticoagulants are used by millions of people every day to lower their risk of stroke. The most common blood thinner is warfarin, also known as Coumadin. In recent years, three new anticoagulants -- Pradaxa, Eliquis and Xarelto -- are threatening Coumadin's status as the most prescribed anticoagulant. Richard Kovacs, M.D., clinical director for the Krannert Institute of Technology, stopped by "Sou.... (Source: Sound Medicine)
Source: Sound Medicine - July 28, 2013 Category: Global & Universal Authors: Sound Medicine Source Type: news

ORBIT-AF: Aspirin With Oral Anticoagulation in AFORBIT-AF: Aspirin With Oral Anticoagulation in AF
An analysis suggests it happens about 40% of the time, even though vascular disease would have to be present to at least justify aspirin, according to guidelines. Even in AF patients with vascular disease, there seems to be no clear pattern explaining observed variation in aspirin use with warfarin in AF. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aspirin often added to warfarin in AF without CAD, despite bleeding risk
An analysis suggests it happens about 40% of the time, even though vascular disease would have to be present to at least justify aspirin, according to guidelines. Even in AF patients with vascular disease, there seems to be no clear pattern explaining observed variation in aspirin use with warfarin in AF. (Source: theHeart.org)
Source: theHeart.org - July 19, 2013 Category: Cardiology Source Type: news

Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding
The novel anticoagulant can now be considered for both acute and extended treatment of VTE, with a lower risk of major bleeding than standard treatment with enoxaparin and warfarin. (Source: Consultant Live)
Source: Consultant Live - July 18, 2013 Category: Primary Care Source Type: news

Benefits Of Pradaxa Maintained In Difficult To Treat Patients With Atrial Fibrillation And Symptomatic Heart Failure
Published in the European Journal of Heart Failure[1], results from a new sub-analysis of the RE-LY®i trial demonstrate important benefits of Pradaxa® (dabigatran etexilate) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation (AF) and previous symptomatic heart failure (HF)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 17, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Novel Anticoagulants: Dosing Errors and Solutions
The half-lives of all the novel anticoagulants are much shorter than that of warfarin and so adherence to dosing regimen and medication error are significant issues. (Source: Consultant Live)
Source: Consultant Live - July 9, 2013 Category: Primary Care Source Type: news

From Rivaroxaban to Warfarin: How to Switch, Safely
Oral anticoagulation with rivaroxaban must continue while initiating a switch to warfarin. Duration of overlap will be variable. Here, guidance from the European Heart Rhythm Association. (Source: Consultant Live)
Source: Consultant Live - July 9, 2013 Category: Primary Care Source Type: news

Development of Predictive Models for Estimating Warfarin Maintenance Dose Based on Genetic and Clinical Factors
In this chapter, we use calculation of estimated warfarin maintenance dosage as an example to illustrate how to develop a multiple linear regression model to quantify the relationship between several independent variables (e.g., patients’ genotype information) and a dependent variable (e.g., measureable clinical outcome). (Source: Springer protocols feed by Pharmacology/Toxicology)
Source: Springer protocols feed by Pharmacology/Toxicology - July 8, 2013 Category: Drugs & Pharmacology Source Type: news

Apixaban Noninferior to Warfarin for Preventing Recurrent VTE (FREE)
By Kelly Young Oral apixaban appears to be as effective as conventional therapy for treating acute venous thromboembolism (VTE), according to an industry-conducted, noninferior study in the New England Journal of … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 8, 2013 Category: Primary Care Source Type: news

Pricey New Blood Thinner Might Be Safer for Leg Clots
In trial, Eliquis worked as well as warfarin but with less risk of bleeding (Source: WebMD Health)
Source: WebMD Health - July 2, 2013 Category: Consumer Health News Source Type: news

Apixaban vs Standard Anticoagulation in Acute VTEApixaban vs Standard Anticoagulation in Acute VTE
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Pricey New Blood Thinner Might Be Safer for Leg Clots
In trial, Eliquis worked as well as warfarin but with less risk of bleeding Source: HealthDay Related MedlinePlus Pages: Blood Thinners, Deep Vein Thrombosis, Pulmonary Embolism (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 1, 2013 Category: Consumer Health News Source Type: news

AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. (Source: theHeart.org)
Source: theHeart.org - July 1, 2013 Category: Cardiology Source Type: news

Release of Eliquis blood clot preventer story
(Reuters) The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - June 30, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

New clot preventer works as well as warfarin with less bleeding
(Reuters) - The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - June 30, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Does ASA or Warfarin Affect the Accuracy of FOBT?Does ASA or Warfarin Affect the Accuracy of FOBT?
Could ASA or warfarin affect the results of a FOBT and, if so, should patients refrain from taking these drugs prior to the test? Journal of Gastroenterology and Hepatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Xarelto Stands Up to Warfarin for Afib (CME/CE)
(MedPage Today) -- Rivaroxaban (Xarelto) worked as well as warfarin in preventing strokes in patients with atrial fibrillation, even if the patients were switched from vitamin K antagonist therapy, an analysis of the ROCKET AF trial showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 17, 2013 Category: Consumer Health News Source Type: news

Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use - Nishijima DK, Shahlaie K, Sarkar K, Rudisill N, Holmes JF.
The objective was to compare neurological outcomes at 6 months in older patients with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage with those without prior use of these medications. METHODS: This was a r... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - June 17, 2013 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Warfarin Lot Recalled, Tablets Too Large
(MedPage Today) -- The maker of a 2 mg warfarin tablet has recalled one lot of the drug because of oversized tablets, which may increase bleeding risks, the FDA said in a statement. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 13, 2013 Category: Cardiology Source Type: news

Oversized 2-mg warfarin tablets recalled
One lot (#MM5767) made by Zydus Pharmaceuticals may include pills that contain an increased pharmacological effect, due to their larger size. (Source: theHeart.org)
Source: theHeart.org - June 13, 2013 Category: Cardiology Source Type: news

Oversized 2-mg Warfarin Tablets RecalledOversized 2-mg Warfarin Tablets Recalled
One lot (#MM5767) made by Zydus Pharmaceuticals may include pills that contain an increased pharmacological effect, due to their larger size. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 13, 2013 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Oversized Warfarin Tablets Recalled
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 13, 2013 Category: Primary Care Tags: Medical News Source Type: news

Warfarin 2 mg Tablets by Zydus Pharmaceuticals USA Inc.: Recall - Due to Oversized Tablets
Ingestion of a greater than intended dose of Warfarin, could lead to an increased pharmacological effect of warfarin. As a result, patients would be more likely to develop bleeding and in some patients that bleeding into a critical organ could be fatal. (Source: FDA MedWatch)
Source: FDA MedWatch - June 13, 2013 Category: American Health Source Type: news

Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
Zydus Pharmaceuticals USA Inc. is voluntarily recalling one lot of Warfarin 2 mg Tablets, Lot # MM5767, expiration date June 2014 to the retail level. Four tablets of Warfarin 2 mg Tablets, Lot MM5767, have been found to be oversized in one product complaint. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 12, 2013 Category: Food Science Source Type: news

2 Pradaxa Doses Beat Warfarin in Afib (CME/CE)
(MedPage Today) -- Considering both efficacy and safety, both the 110-mg and 150-mg doses of dabigatran (Pradaxa) had a net clinical benefit compared with warfarin in patients with atrial fibrillation, researchers found. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 12, 2013 Category: Consumer Health News Source Type: news

Safe for Stroke Patients to Continue Blood Thinners before Minor Surgical Procedures
June 6, 2013 - Many patients who have experienced strokes or mini strokes take blood thinners such as aspirin or warfarin (Coumadin) to reduce the risk of blood clots that can cause strokes. (Source: NurseZone.com Nursing News)
Source: NurseZone.com Nursing News - June 7, 2013 Category: Nursing Source Type: news

Genetics of Warfarin Dosing in African AmericansGenetics of Warfarin Dosing in African Americans
Patients carrying the SNP, which is located in the CYP2C9 gene, require a significantly lower stable dose of warfarin than do those without the variant, say researchers. The addition of the SNP also improved the International Warfarin Pharmacogenetics Consortium treatment algorithm by 21%. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 6, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

SNP influencing warfarin dose identified in African Americans
Patients carrying the SNP, which is located in the CYP2C9 gene, require a significantly lower stable dose of warfarin than do those without the variant, say researchers. The addition of the SNP also improved the International Warfarin Pharmacogenetics Consortium treatment algorithm by 21%. (Source: theHeart.org)
Source: theHeart.org - June 6, 2013 Category: Cardiology Source Type: news

Researchers Uncover Genetic Key For Improved Blood-Thinning Therapy For African-American Patients
Researchers have discovered a way to make a blood thinner safer for about 40 percent of African-Americans taking the drug by linking a common gene variation to the dose. These findings, published June 4 EDT in The Lancet, are the latest results from ongoing collaborative work by 42 researchers from 17 institutions in the International Warfarin Pharmacogenetics Consortium led by University of Florida Health researcher Julie A. Johnson, a distinguished professor of pharmacy and medicine and director of the UF Center for Pharmacogenomics... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 6, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Genetic Variations Impact Warfarin Doses For African Americans
A common genetic variation that can impact the therapeutic dose of the blood-thinning drug warfarin among African Americans has been found, according to a new report in The Lancet. The finding revealed that people of African ancestry who have the rs12777823 variant require a notably lower dose of warfarin to achieve all the advantages, compared to those without this single-nucleotide polymorphism (SNP)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 6, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Blacks with Certain Gene Need Lower Doses of Warfarin
More than 40 percent have the variation, which affects their response to the common blood thinner Source: HealthDay Related MedlinePlus Pages: African American Health, Blood Thinners, Genes and Gene Therapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 5, 2013 Category: Consumer Health News Source Type: news

Blacks With Certain Gene Need Lower Doses of Warfarin: Study
Title: Blacks With Certain Gene Need Lower Doses of Warfarin: StudyCategory: Health NewsCreated: 6/5/2013 10:35:00 AMLast Editorial Review: 6/5/2013 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 5, 2013 Category: Cardiology Source Type: news

Making ICD Surgery Safer
(Ivanhoe Newswire) – A clinical trial coordinated by the University of Ottawa Heart Institute Cardiovascular Research Methods Centre has found that as compared to bridging therapy with heparin, continued warfarin treatment at the time of pacemaker or ICD surgery markedly reduced the incidence of clinically significant device-pocket hematoma, which was defined as device-pocket hematoma that prolonged hospitalization, interruption of anticoagulation therapy, or further surgery. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - June 5, 2013 Category: Consumer Health News Source Type: news

Gene Variant in Blacks Alters Warfarin Response (CME/CE)
(MedPage Today) -- The first genome-wide association study to focus on warfarin dose in African Americans found a genetic variant that explains their variable response to the blood thinner. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 5, 2013 Category: Cardiology Source Type: news

Comparing the New Blood Thinners to Warfarin
Title: Comparing the New Blood Thinners to WarfarinCategory: Health NewsCreated: 6/1/2013 11:00:00 AMLast Editorial Review: 6/3/2013 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 3, 2013 Category: Cardiology Source Type: news